GLOW BlendWhat the studies show

The study behind GHK-Cu's skin reputation is from 1988. Human skin fibroblasts, the cells that make collagen, were grown with the peptide and made measurably more of it, in proportion to the amount added ⁴. A 2018 review by the researcher who discovered the peptide collects the rest: faster wound closure in rats, mice, rabbits, pigs and dogs, and small cosmetic trials of creams that reported thicker and more elastic skin over 12 weeks, measured by instruments and by dermatologists ¹. The cosmetic trials are small, and most were paid for by the companies selling the creams. There is no large placebo-controlled trial of GHK-Cu for anything, and the human data are for creams on skin, not for anything injected.

In 2003, rats with a cut Achilles tendon were given BPC-157 or saline; the treated tendons were stronger and better organised at every time point measured, whether the peptide was injected or given by mouth ². A 2017 study asked how, and found that the peptide increased the growth of new blood vessels in rat tissue and in cultured vessel-lining cells through VEGFR2, the main receptor that drives vessel growth; blocking the receptor removed the effect ⁵. There is no completed placebo-controlled trial of BPC-157 in people. Nearly everything comes from one research group in Zagreb and its rats, and a rat tendon is not a human tendon.

Thymosin beta-4 binds actin, the protein cells use to move and change shape, and that is thought to be why it turns up wherever tissue is being rebuilt. In a 1999 study, full-thickness wounds on rats closed faster when thymosin beta-4 was applied to the wound or injected, with more collagen laid down and more cells migrating into the wound bed ³. Later animal work covered the cornea, the heart after a blocked artery and the skin, and the protein went into small trials in people as an eye drop for dry eye and as a gel for chronic ulcers; a 2012 review collects both ⁶. None of those trials has led to an approved product. The thymosin beta-4 in that research is the full protein, so results from it do not automatically transfer to a fragment of it.

No published study has given GHK-Cu, BPC-157 and TB-500 together, to animals or to people, so there is no data on whether their effects add, cancel or interact. The combination is a product idea, not a research finding. Each component's evidence sits at a different level: GHK-Cu has cell work plus small cosmetic trials of creams, BPC-157 has rats, thymosin beta-4 has animals plus a few small trials of the whole protein. Reading the three records as one, or assuming a blend inherits the best result from each, is the mistake to avoid.